Left Ventricular Assist Devices Market Report 2026

Left Ventricular Assist Devices Market Overview

• Left Ventricular Assist Devices market size has reached to $1.73 billion in 2025 • Expected to grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Elevated Cardiovascular Disease Rates Propel Left Ventricular Assist Device Market • Market Trend: CorWave Achieves First Human Implant of Innovative Heart Pump Delivering Physiological Pulsatile Flow • North America was the largest region in 2025.

What Is Covered Under Left Ventricular Assist Devices Market?

The left ventricular assist device is a mechanical pump implanted in heart failure patients. The device aids in the heart's lower left chamber (left ventricle), pumping blood to the aorta and the rest of the body. The main types of left ventricular assist devices are transcutaneous left ventricular assist devices and implantable left ventricular assist devices. A transcutaneous left ventricular assist device refers to a pump that has an external power supply and an internal pump that are both located inside the body. Through tiny openings in the abdomen, tubes link the pump to the heart. Short-term support during or following surgery may be provided by this kind of left ventricular assist device. Pulsatile and non-pulsatile are the types of flows of left ventricular assist devices that are used in bridge-to-recovery (BTR) therapy, bridge-to-transplant (BTT) therapy, destination therapy, and bridge-to-candidacy (BTC) therapy by cardiology centers and hospitals.

What Is The Left Ventricular Assist Devices Market Growth Forecast?

The left ventricular assist devices market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing aging population with cardiac conditions, rising demand for long-term heart failure management solutions, advancements in biocompatible materials, growing integration of remote monitoring technologies, expanding reimbursement coverage for lvads. Major trends in the forecast period include increasing adoption of continuous flow lvads, rising use of lvads as destination therapy, growing focus on miniaturized implantable pumps, expansion of remote patient monitoring capabilities, enhanced emphasis on device durability and longevity.

Global Left Ventricular Assist Devices Market Segmentation

1) By Type: Percutaneous Left Ventricular Assist Devices, Implantable Left Ventricular Assist Devices 2) By Type Of Flow: Pulsatile, Non-Pulsatile 3) By Application: Bridge-To-Recovery (BTR) Therapy, Bridge-To-Transplant (BTT) Therapy, Destination Therapy, Bridge-To-Candidacy (BTC) Therapy 4) By End-User: Cardiology Centers, Hospitals Subsegments: 1) By Percutaneous Left Ventricular Assist Devices: Axial-Flow Percutaneous LVADs, Centrifugal-Flow Percutaneous LVADs 2) By Implantable Left Ventricular Assist Devices: Continuous Flow Devices, Pulsatile Flow Devices

What Is The Driver Of The Left Ventricular Assist Devices Market?

The rising prevalence of cardiovascular diseases is expected to propel the growth of the left ventricular assist device market going forward. Cardiovascular diseases refer to a group of disorders of the heart and blood vessels. It includes coronary heart disease, congenital heart disease, and others. In the case of advanced heart failure, a left ventricular assist device assists the heart's left ventricle, which pumps blood to the body's tissues. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the left ventricular assist device industry.

Key Players In The Global Left Ventricular Assist Devices Market

Major companies operating in the left ventricular assist devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, St. Jude Medical, MAQUET GmbH & Co., LivaNova Plc, Thoratec Corporation, Abiomed Inc, Berlin Heart GmbH, BioVentrix, Cleveland Heart Inc., Jarvik Heart Inc., CorWave SA, SynCardia Systems LLC, NuPulseCV Inc., Fineheart, Procyrion Inc, Carmat SA, BiVACOR Inc, Cardiac Assist Inc., Leviticus Cardio Ltd., Calon Cardio-Technology Ltd, Evaheart Inc., Sunshine Heart Inc., CH Biomedical Inc.

Global Left Ventricular Assist Devices Market Trends and Insights

Major companies operating in the left ventricular assist devices market are focusing on developing advanced solutions, such as wave membrane technology, to replace traditional rotary LVADs. A wave membrane solution refers to a next-generation heart pump designed to reproduce physiological pulsatility and blood flow velocities similar to a healthy heart, potentially reducing complications associated with current devices. For instance, in September 2025, CorWave SA, a France-based medical device company, implanted its Left Ventricular Assisting System (LVAS) into a patient for the first time at St Vincent’s Hospital in Sydney. This innovation provides full cardiac support, efficiently unloading the left ventricle while preserving an aortic pulse pressure of 25.5 ± 6.1 mmHg and consistent aortic valve opening. The device achieved primary study endpoints with no device-related adverse events at 30 days, and the patient successfully underwent heart transplantation after 84 days on support. CorWave’s LVAS represents a major technological milestone in durable mechanical circulatory support by delivering safe, physiological pulsatile flow that can improve patient outcomes and advance heart failure management.

What Are Latest Mergers And Acquisitions In The Left Ventricular Assist Devices Market?

In March 2025, Abbott Laboratories, a US-based healthcare technology company, entered into a collaboration agreement with Cadrenal Therapeutics, Inc. for an undisclosed amount. With this agreement, Abbott aimed to support Cadrenal in conducting a pivotal clinical trial of tecarfarin in patients with HeartMate 3 LVADs, enhancing its strategic position in advanced heart failure management and clinical innovation. Cadrenal Therapeutics Inc. is a US-based biopharmaceutical company that specializes in developing novel anticoagulant therapies, including tecarfarin, for patients with cardiovascular devices such as left ventricular assist devices.

Regional Outlook

North America was the largest region in the left ventricular assist devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Left Ventricular Assist Devices Market?

The left ventricular assist devices market consists of sales of rechargeable left ventricular assist devices, non-rechargeable left ventricular assist devices, heart pumps, and controllers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.